BridgeBio Oncology Touts “Best in RAS” Pipeline, Highlights BBO-8520 Response and Combo Tolerability
BBO-8520: KRAS G12C on/off inhibitor showed a 65% response rate and 68% six‑month PFS across dose levels, with low liver toxicity as monotherapy and in combination with pembrolizumab; all three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results